BioCentury | Jul 10, 2014
Distillery Therapeutics

Indication: Cancer

...MAO-A in patients with prostate cancer. Krenitsky Pharmaceuticals Inc. has the reversible MAO-A inhibitor TriRima (KP157...
BioCentury | Jan 10, 2011
Clinical News

TriRima: Phase II started

...trial to evaluate 125 mg TriRima twice daily in 360 patients. CeNeRx has rights to TriRima...
...N.C. Krenitsky Pharmaceuticals Inc. , Durham, N.C. Product: TriRima ( KP157 ) (formerly CX157 , Tyrima...
BioCentury | Aug 13, 2010
Financial News

CeNeRx raises $13 million

...start a Phase II trial for TriRima as monotherapy for treatment-resistant depression by year end. TriRima...
...A (MAO-A) that elevates the levels of serotonin, norepinephrine and dopamine. CeNeRx has rights to TriRima...
BioCentury | Jun 22, 2009
Company News

CeNeRx, Krenitsky Pharmaceuticals deal

...chemotherapy-induced peripheral neuropathy this year. Financial terms were not disclosed. CeNeRx's lead is TriRima (formerly Tyrima...
...norepinephrine and dopamine is in Phase II testing to treat depression. CeNeRx has rights to TriRima...
BioCentury | Oct 20, 2008
Clinical News

Tyrima: Phase II started

...CeNeRx began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 60 mg of oral Tyrima...
...6 weeks in about 272 patients. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...
BioCentury | Oct 18, 2008
Financial News

CeNeRx raises $15 million

...by existing investor Aisling. L Capital Partners and Pappas Ventures, also existing investors, participated. CeNeRx's Tyrima...
BioCentury | Jul 28, 2008
Clinical News

Tyrima: Phase II start

...oral Tyrima in over 270 patients. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...
BioCentury | Jan 21, 2008
Clinical News

Tyrima: Phase I data

...company’s Phase I program, which included acute dosing, repeat dosing and fed-fasted studies, showed that Tyrima...
...allow for once- or twice-daily dosing. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...
BioCentury | Mar 19, 2007
Clinical News

Tyrima: Phase I data

...In a single-dose, dose-escalation, placebo-controlled, U.S. Phase I trial in 41 healthy volunteers, Tyrima was well...
...is slated to being next quarter. CeNeRx BioPharma Inc. , Cary, N.C. Product: Tyrima (formerly CX157...
BioCentury | Feb 5, 2007
Product Development

Safer RIMA

...are used sparingly because of potentially lethal dietary and drug interactions. CeNeRx BioPharma Inc. believes Tyrima...
...aged meats and cheeses. Elevated tyramine can result in hypertensive crisis. CEO Barry Brand said Tyrima...
...Phase I testing of Tyrima in 1H07. Brand said the company also will administer both Tyrima...
Items per page:
1 - 10 of 13